The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,246.00
Bid: 12,254.00
Ask: 12,256.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK FCA charges NatWest with money-laundering failures

Tue, 16th Mar 2021 08:20

(Alliance News) - The City watchdog has launched criminal proceedings against taxpayer-backed lender NatWest Group for alleged failures under money laundering rules, PA reported Tuesday.

The Financial Conduct Authority alleges that "increasingly large cash deposits" were made into a NatWest customer's account, with around GBP365 million paid in – of which some GBP264 million was in cash.

It claims that NatWest's systems and controls failed to properly monitor and scrutinise this activity, which took place between November 11 2011 and October 19 2016.

NatWest is due to appear at Westminster Magistrates' Court on April 14.

It marks the first time the FCA has launched criminal prosecution under the money laundering regulations and the first time the rules have been used to prosecute a bank.

The FCA said the money laundering rules require firms to "determine, conduct and demonstrate risk sensitive due diligence and ongoing monitoring of its relationships with its customers for the purposes of preventing money laundering".

No individuals are being charged as part of the proceedings.

NatWest shares were down 0.8% early Tuesday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.5% at 6,784.44

----------

Hang Seng: up 0.7% at 29,020.58

Nikkei 225: closed up 0.5% at 29,921.09

DJIA: closed up 174.82 points, 0.5%, at 32,953.46

S&P 500: closed up 0.7% at 3,968.94

Nasdaq Composite: closed up 1.1% at 13,459.71

----------

EUR: down at USD1.1922 (USD1.1931)

GBP: down at USD1.3832 (USD1.3885)

USD: up at JPY109.21 (JPY109.08)

Gold: down at USD1,728.85 per ounce (USD1,730.28)

Oil (Brent): down at USD68.23 a barrel (USD68.70)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Tuesday's Key Economic Events still to come

US Federal Open Market Committee meeting starts

1100 CET Germany ZEW Indicator

0830 EDT US import & export price indexes

0830 EDT US retail sales

0855 EDT US Johnson Redbook retail sales index

0915 EDT US industrial production

1000 EDT US NAHB housing market index

1630 EDT US API Weekly statistical bulletin

----------

US and Japanese foreign and defence ministers warned on China, saying they had renewed a commitment to opposing "coercion and destabilising behaviour," during talks in Tokyo. "The US and Japan acknowledged that China's behaviour, where inconsistent with the existing international order, presents political, economic, military and technological challenges," they said in a joint statement on Tuesday. "The ministers committed to opposing coercion and destabilising behaviour towards others in the region," they added.

----------

BROKER RATING CHANGES

----------

JEFFERIES RAISES ASTRAZENECA TO 'BUY' (HOLD) - PRICE TARGET 8850 (8250) PENCE

----------

CREDIT SUISSE RAISES NATWEST TO 'OUTPERFORM' ('NEUTRAL') - TARGET 230 (170) P

----------

CREDIT SUISSE RAISES HSBC TO 'NEUTRAL' (UNDERPERFORM) - PRICE TARGET 440 (400) PENCE

CREDIT SUISSE RAISES BARCLAYS TO 'OUTPERFORM' (NEUTRAL) - PRICE TARGET 210 (155) PENCE

----------

BERENBERG INITIATES B&M EUROPEAN VALUE RETAIL WITH 'BUY' - TARGET 600 PENCE

----------

COMPANIES - FTSE 100

----------

AstraZeneca said it has modified an existing agreement with the US government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody combination which is in late-stage development for the prevention and treatment of Covid-19. The Anglo-Swedish drugmaker said the new US government deal builds on earlier deals for a total of 200,000 doses with the US Department of Health & Human Service and Department of Defense. The value of the extended agreement is USD205 million and is contingent on AZD7442 receiving and Emergency Use Authorisation from the US Food & Drug Administration. AstraZeneca said the total value of current agreements with the US government for the development and supply of AZD7442 in 2021 is about USD726 million. The extended agreement is not anticipated to effect the company's financial guidance for 2021.

----------

AstraZeneca also said it has completed the sale of its 27% stake in Viela Bio Inc to Horizon Therapeutics. It will receive USD775 million in cash proceeds and profit from the Viela stake sale, but this also isn't expected to affect its guidance for 2021.

----------

Chilean copper miner Antofagasta hiked its dividend as it reported positive annual results and a strengthened balance sheet. For 2020, revenue was up 3.3% to USD5.13 billion from USD4.94 billion in 2019. Pretax profit was USD1.41 billion, up 4.4% from USD1.35 billion. Earnings before interest, tax, depreciation and amortisation rose 12% to USD2.74 billion in 2020 from USD2.44 billion the year prior. The miner declared a final dividend of 48.5 cents per share, bringing the total dividend for the year to 54.7 cents per share, up from 17.8 cents in 2019. Chief Executive Ivan Arriagada said: "The year has been challenging, but we have successfully kept our people safe and healthy, achieved our production and exceeded our cost targets, and increased Ebitda by 12.3% to USD2.7 billion, yielding a 53% Ebitda margin...Our resilient operations performed well with high levels of throughput and our Cost & Competitiveness Programme delivered benefits of USD197 million, nearly double the targeted amount. Our balance sheet strengthened even further." Antofagasta said it had USD82 million in net debt at the end of 2020, for a net debt to Ebitda ratio of just 0.03 times.

----------

Plumbing and heating products supplier Ferguson said it delivered good top-line growth in the first half of its financial year and despite "challenging personal and professional" circumstances. For the half year ended January 31, revenue was up 4.2% to USD10.31 billion from USD9.89 billion at the same time the year before, and pretax profit rose 18% to USD739 million from USD628 million. Ferguson declared an interim dividend of 72.9 US cents, having paid out nothing the year before and said that now the disposal of its UK side has completed, a special dividend of 180 cents per share will be paid in May. It also announced a new USD400 million share buy back scheme. Ferguson completed the GBP308 million sale of heating & plumbing distribution business Wolseley UK to US private equity firm Clayton, Dubilier & Rice at the start of February.

----------

COMPANIES - FTSE 250

----------

Stockbroker AJ Bell confirmed it has picked Helena Morrissey as its next chair. Morrissey will join the AJ Bell board as chair designate on July 1 and succeed Les Platts as chair at the next annual general meeting in January next year. Morrissey will step down as a non-executive director of wealth manager St James's Place on July 1 "to avoid any potential conflict of interest", St James's Place said. Morrissey was head of Personal Investing at Legal & General Investment Management and prior to that chief executive of Newton Investment Management.

----------

COMPANIES - GLOBAL

----------

Credit Suisse confirmed that it has made "a strong start" to 2021, achieving the highest level of pretax income in both January and February in a decade. The Swiss bank said its Investment Bank division is benefiting from a "particularly strong" performance in capital markets issuance activity and from a continued "good" performance across sales & trading. Investment Bank year-to-date revenue is up over 50% compared to the prior year, Credit Suisse noted. It also reported increased client activity year-on-year, which was boosting all of its three Wealth Management-related businesses, while net interest income was also stabilising and recurring commissions and fees continued to trend up. "Notwithstanding the continued Covid-19 pandemic, our credit loss experience remains benign, with signs of improvement in the global economy beginning to benefit allowance for credit losses under the current expected credit loss accounting methodology," said Chief Executive Thomas Gottstein. Turning to the suspension and liquidation of the supply chain finance funds - with net asset value of USD10 billion - managed by Credit Suisse Asset Management with assets originated and structured by Greensill Capital, Credit Suisse said its priority remains the recovery of funds for its investors.

----------

Tuesday's Shareholder Meetings

Blackrock Energy & Resources Income Trust PLC - AGM

Blue Prism Group PLC - AGM

Plus500 Ltd - EGM

Starvest PLC - AGM

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.